PCV13 Impact on Pneumococcal Nasopharyngeal Carriage Study

Inclusion Criteria: 1. Child 8 weeks to ≤60 months of age 2. Resident of the National Capital Region (NCR) or Region X-XIII 3. Child admitted with a medical diagnosis of clinical CAP based on history and physical exam 4. Written informed consent obtained from a parent or legal guardian 5. At SPMC site, child must have received at least 1 dose of PCV13 given at \<12 months based on history-taking 6. For Phase B at PCMC site, child must have received at least 1 dose of PCV13 given at \<12 months based on history-taking Exclusion Criteria: 1. Children with a known primary or secondary immunodeficiency 2. Child with a contraindication to doing a nasopharyngeal swab which may include, but is not limited to: dyscrasias, coagulation disorders, or other diseases (e.g., hemophilia, purpura), presence of craniofacial abnormalities32 3. For Phase A at PCMC site, child with any PCV in the past based on history-taking